AbCellera Biologics (ABCL) Intangibles (2020 - 2026)

AbCellera Biologics' Intangibles history runs 7 years deep, the most recent figure standing at $37.5 million for Q1 2026.

• Quarterly Intangibles fell 9.06% year-over-year to $37.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.5 million (down 9.06% YoY) and the FY2025 annual result came in at $38.4 million, down 8.86% from the prior year.
• Intangibles was $37.5 million for Q1 2026 at AbCellera Biologics, down from $38.4 million in the prior quarter.
• Across five years, Intangibles topped out at $161.0 million in Q1 2022 and bottomed at $37.5 million in Q1 2026.
• A 5-year average of $92.6 million and a median of $118.7 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles soared 1063.73% — and 2025, when it sank 65.31%.
• AbCellera Biologics' Intangibles stood at $131.5 million in 2022, then dropped by 8.42% to $120.4 million in 2023, then slumped by 65.03% to $42.1 million in 2024, then declined by 8.86% to $38.4 million in 2025, then declined by 2.4% to $37.5 million in 2026.
• Business Quant data shows ABCL's Intangibles at $37.5 million in Q1 2026, $38.4 million in Q4 2025, and $39.3 million in Q3 2025.